CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Frequently asked questions
What sector does CanSino Biologics Inc (CASBF) operate in?
CanSino Biologics Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is CanSino Biologics Inc (CASBF) current stock price?
As of the latest data, CanSino Biologics Inc stock price is $3.95, with a previous close of $3.95.
What is CanSino Biologics Inc (CASBF) current market capitalization?
CanSino Biologics Inc market cap is approximately 524.05 million.
What is CanSino Biologics Inc (CASBF) Earnings Per Share (EPS)?
The trailing EPS is $0.02.
What is CanSino Biologics Inc (CASBF) Price-to-Earnings (P/E) ratio?
CanSino Biologics Inc current P/E ratio is 197.5.
What is CanSino Biologics Inc (CASBF) EBITDA?
CanSino Biologics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 60.37 million.
Does CanSino Biologics Inc (CASBF) pay dividends?
No. CanSino Biologics Inc does not pay a dividend.
What is CanSino Biologics Inc (CASBF) beta (volatility) score?
CanSino Biologics Inc has a beta of 1.128, meaning its volatility is roughly in line with the market.
